Quantcast

Latest Cancer immunotherapy Stories

2014-06-01 08:20:34

NKTR-214 combined with anti-PD-1 or anti-CTLA-4 provides significant tumor growth inhibition in both EMT6 breast and CT26 colon tumor models SAN FRANCISCO, June 1, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which selectively activates the IL-2 receptor complex and is being developed as a potential treatment for multiple cancers. The results were presented today at the 2014 ASCO...

2014-05-30 08:25:21

SANTA MONICA, Calif., May 30, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the Company will provide details on key features of the rapid, 6-day manufacturing process that is expected to underlie its most advanced personalized cancer immunotherapy program. The technology is expected to underpin a Kite clinical trial in...

2014-05-29 12:29:19

PRINCETON, N.J., May 29, 2014 /PRNewswire/ -- inVentiv Health Clinical, a leading global clinical research organization (CRO), and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing cancer immunotherapies, announced today that they have entered into a global master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline. inVentiv initially will work with Advaxis to develop clinical study protocols and will...

2014-05-28 16:26:55

Educational and Awareness Raising Events Scheduled throughout the Month of June NEW YORK, May 28, 2014 /PRNewswire/ -- The Cancer Research Institute (CRI) is pleased to host its second annual Cancer Immunotherapy Month in June, aimed at increasing awareness of cancer immunotherapy, also known as immuno-oncology, a class of cancer treatment that mobilizes the immune system to fight the disease. Immunotherapy was named Science magazine's 2013 Breakthrough of the Year, and is anticipated once...

2014-05-28 08:31:36

-- Ongoing Phase 1 Cancer Immunotherapy Study to be Presented at the Annual Meeting of the American Society of Clinical Oncology -- REDWOOD CITY, Calif., May 28, 2014 /PRNewswire/ -- ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced it raised $30 million in a Series B private financing led by NanoDimension. Existing investors Kleiner Perkins Caufield & Byers, OrbiMed and DAG Ventures also participated in the round. "This financing validates both...

2014-05-27 12:32:22

SEATTLE, May 27, 2014 /PRNewswire/ -- Adaptive Biotechnologies, the pioneer of Next Generation Sequencing of the adaptive immune system, and its collaborators will present data supporting the clinical application of immunosequencing in diagnosing and monitoring T cell lymphomas at the 2014 Annual Meeting of the American Society of Clinical Oncology. Data will also be presented demonstrating how immunosequencing can be used to elucidate the activity of immunotherapeutic combination...

2014-05-26 13:21:07

University of Texas M. D. Anderson Cancer Center Peptide antibodies hit immune-response-stifling MDSCs without harming other vital cells Scientists have found a way to target elusive cells that suppress immune response, depleting them with peptides that spare other important cells and shrink tumors in preclinical experiments, according to a paper published online by Nature Medicine. "We've known about these cells blocking immune response for a decade, but haven't been able to shut...

2014-05-15 23:00:47

Created by Society for Immunotherapy of Cancer, this video was created to raise awareness about the excitement and the hope cancer immunotherapy clinical trials can offer patients with NSCLC today. Milwaukee, WI (PRWEB) May 15, 2014 A recently released video on cancer immunotherapy is offering new hope to patients with non-small cell lung cancer (NSCLC), the type of cancer which makes up 85% to 90% of all lung cancer cases in the US and claims more lives each year than colon, breast, and...

2014-05-12 08:30:31

BLUE BELL, Pa., May 12, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2014. Total revenue was $2.4 million for the three months ended March 31, 2014, compared to $1.5 million for the same period in 2013. Total operating expenses were $12.4 million compared to $8.1 million. The loss from operations prior to other income (expenses) for the quarter ended March 31, 2014, was $10.0 million, or $0.05...

2014-05-08 12:29:37

Tumors shrank or disappeared in some patients with advanced neuroblastoma in a Phase I study of an immune therapy manufactured at St. Jude Children's Research Hospital MEMPHIS, Tenn., May 8, 2014 /PRNewswire-USNewswire/ -- Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital. Four patients are still alive after more...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related